RXi Pharmaceuticals Appoints H. Paul Dorman and Curtis Lockshin, Ph.D. to Board of Directors
News Apr 23, 2013
Mr. Dorman brings nearly three decades of executive experience in the pharmaceutical industry with Johnson & Johnson and Baxter, in various leadership roles, to RXi. He currently serves as Chairman and CEO of DFB Pharmaceuticals, a Fort Worth, TX based holding company that, over the last 20 years, has successfully invested in and operated multiple pharmaceutical businesses. In that role, he acquired several companies, three of which were turned around to profitability, from Chapter 11 status at acquisition, and later sold to a large, multi-national, public corporation. He holds a Bachelor of Science degree in Mechanical Engineering from Tulane University and a Juris Doctor of Law from Loyola University. “Mr. Dorman is one of the remarkable icons in the healthcare industry and we are thrilled to have him join our Board,” said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, “Paul’s experience and network in both the large and small pharma world, as well as his wisdom in leading companies to success, will be major contributing factors to the RXi Board of Directors and the growth of our Company.”
Dr. Lockshin comes to RXi providing exceptional industry insight and functional, hands-on experience. Most recently, he has been an Independent Pharmaceutical & Life Sciences Consultant for OPKO Health, Inc. Prior to this role, Dr. Lockshin served as Vice President, Corporate R&D Initiatives for OPKO Health, Inc., with operational responsibilities inside several of OPKO's R&D units. He currently serves as a Director of the Ruth K. Broad Biomedical Research Foundation, a Duke University Support Corporation. He previously served as a Director of Sorrento Therapeutics and Winston Pharmaceuticals. He initially began his career as a scientist with Sepracor and eventually became the research director responsible for the strategy and operations of Sepracor's new leads initiative. He is a Co-Inventor on several U.S. patents and applications, covering pharmaceuticals, biomaterials, and optics for remote biochemical sensing. Dr. Lockshin holds a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology. “Dr. Lockshin has an impressive career track record in research and development of new drugs”, commented Dr. Geert Cauwenbergh. “With RXi Pharmaceuticals in the midst of a game changing drug in development with RXI-109 for dermal scarring, Curt will provide valuable insights into the development of our drugs. With Paul Dorman and Curt Lockshin joining our current Board members Bob Bitterman and Keith Brownlie, RXi Pharmaceuticals has a well rounded Board of Directors with an appropriate balance of all key elements needed for success.”
In a new study in cells, University of Illinois researchers have adapted CRISPR gene-editing technology to cause the cell’s internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building. This gives researchers a way not only to eliminate a mutated gene sequence, but to influence how the gene is expressed and regulated.